Tanshinone IIA attenuates bleomycin-induced pulmonary fibrosis in rats

Molecular Medicine Reports

Volumn 11, Issue 6, 2015, Pages 4190-4196

  He, Huanyu ^a   Tang, Haiying ^a   Gao, Lili ^a   Wu, Yun ^a   Feng, Zhiqiang ^a   Lin, Hongli ^a   Wu, Taihua ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Bleomycin; Fibrosis; Idiopathic pulmonary fibrosis; Inflammation; Tanshinone IIA

Indexed keywords

CD133 ANTIGEN; MESSENGER RNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN BAX; PROTEIN P53; PUMA PROTEIN; RNA; TEMOZOLOMIDE; ABIETANE DERIVATIVE; ANTINEOPLASTIC ANTIBIOTIC; BLEOMYCIN; CYCLOOXYGENASE 2; HERBACEOUS AGENT; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; TANSHINONE;

ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CANCER SIZE; CANCER STEM CELL; CELL POPULATION; CELL SELECTION; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; FEMALE; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RNA ISOLATION; UPREGULATION; ANIMAL; BIOSYNTHESIS; BRONCHOALVEOLAR LAVAGE FLUID; CELL COUNT; CHEMICALLY INDUCED; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; INFLAMMATION; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; PULMONARY FIBROSIS; RAT;

RATTUS; SALVIA MILTIORRHIZA;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLEOMYCIN; BRONCHOALVEOLAR LAVAGE FLUID; CELL COUNT; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; DITERPENES, ABIETANE; DRUGS, CHINESE HERBAL; INFLAMMATION; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; OXIDATIVE STRESS; PULMONARY FIBROSIS; RATS;

EID: 84924709761     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3333     Document Type: Article

References (46)

1. Wilson MS and Wynn TA: Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol 2: 103-121, 2009.
2. du Bois RM: Strategies for treating idiopathic pulmonary fibrosis. Nat Rev Drug Discov 9: 129-140, 2010.
3. Wynn TA and Ramalingam TR: Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 18: 1028-1040, 2012.
4. Bringardner BD, Baran CP, Eubank TD and Marsh CB: The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis. Antioxid Redox Signal 10: 287-301, 2008.
5. Kliment CR and Oury TD: Oxidative stress, extracellular matrix targets, and idiopathic pulmonary fibrosis. Free Radic Biol Med 49: 707-717, 2010.
6. Fubini B and Hubbard A: Reactive oxygen species (ROS) and reactive nitrogen species (RNS) generation by silica in inflammation and fibrosis. Free Radic Biol Med 34: 1507-1516, 2003.
7. No authors listed: Regulatory watch: First drug for idiopathic pulmonary fibrosis approved in Japan. Nat Rev Drug Discov 7: 966-967, 2008.
8. Moran N: p38 kinase inhibitor approved for idiopathic pulmonary fibrosis. Nat Biotechnol 29: 301, 2011.
9. Zhou L, Zuo Z and Chow MS: Danshen: an overview of its chemistry, pharmacology, pharmacokinetics and clinical use. J Clin Pharmacol 45: 1345-1359, 2005.
10. Chiu SC, Huang SY, Chen SP, Su CC, Chiu TL and Pang CY: Tanshinone IIA inhibits human prostate cancer cells growth by induction of endoplasmic reticulum stress in vitro and in vivo. Prostate Cancer Prostatic Dis 16: 315-322, 2013.
11. Shan YF, Shen X, Xie YK, et al: Inhibitory effects of tanshinone II-A on invasion and metastasis of human colon carcinoma cells. Acta Pharmacol Sin 30: 1537-1542, 2009.
12. Yu T, Zhou Z, Mu Y, de Lima Lopes G and Luo KQ: A novel anti-cancer agent, acetyltanshinone IIA, inhibits oestrogen receptor positive breast cancer cell growth by down-regulating the oestrogen receptor. Cancer Lett 346: 94-103, 2014.
13. Hong HJ, Liu JC, Cheng TH and Chan P: Tanshinone IIA attenuates angiotensin II-induced apoptosis via Akt pathway in neonatal rat cardiomyocytes. Acta Pharmacol Sin 31: 1569-1575, 2010.
14. Gao S, Liu Z, Li H, Little PJ, Liu P and Xu S: Cardiovascular actions and therapeutic potential of tanshinone IIA. Atherosclerosis 220: 3-10, 2012.
15. Chen Y, Wu X, Yu S, et al: Neuroprotection of tanshinone IIA against cerebral ischemia/reperfusion injury through inhibition of macrophage migration inhibitory factor in rats. PLoS One 7: e40165, 2012.
16. Liu Y, Chen H and Jiang Y: Effect of tanshinone IIA on CCl4-induced liver fibrosis in rats. Zhong Yao Cai 25: 31-33, 2002 (In Chinese).
17. Sun RF, Liu LX and Zhang HY: Effect of tanshinone II on hepatic fibrosis in mice. Zhongguo Zhong Xi Yi Jie He Za Zhi 29: 1012-1017, 2009.
18. Chunming J, Miao Z, Cheng S, et al: Tanshinone IIA attenuates peritoneal fibrosis through inhibition of fibrogenic growth factors expression in peritoneum in a peritoneal dialysis rat model. Ren Fail 33: 355-362, 2011 (In Chinese).
19. Walters DM and Kleeberger SR: Mouse models of bleomycin-induced pulmonary fibrosis. Curr Protoc Pharmacol Chapter 5: 46, 2008.
20. Wu Z, Yang L, Cai L, et al: Detection of epithelial to mesenchymal transition in airways of a bleomycin induced pulmonary fibrosis model derived from an alpha-smooth muscle actin-Cre transgenic mouse. Respir Res 8: 1, 2007.
21. Ashcroft T, Simpson JM and Timbrell V: Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 41: 467-470, 1988.
22. Hübner RH, Gitter W, El Mokhtari NE, et al: Standardized quantification of pulmonary fibrosis in histological samples. Biotechniques 44: 507-511, 514-507, 2008.
23. Savas HA, Gergerlioglu HS, Armutcu F, et al: Elevated serum nitric oxide and superoxide dismutase in euthymic bipolar patients: impact of past episodes. World J Biol Psychiatry 7: 51-55, 2006.
24. Dongaonkar RM, Laine GA, Stewart RH and Quick CM: Balance point characterization of interstitial fluid volume regulation. Am J Physiol Regul Integr Comp Physiol 297: R6-R16, 2009.
25. Cheresh P, Kim SJ, Tulasiram S and Kamp DW: Oxidative stress and pulmonary fibrosis. Biochim Biophys Acta 1832: 1028-1040, 2013.
26. Greenhough A, Smartt HJ, Moore AE, et al: The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30: 377-386, 2009.
27. Gawel S, Wardas M, Niedworok E and Wardas P: Malondialdehyde (MDA) as a lipid peroxidation marker. Wiad Lek 57: 453-455, 2004 (In Polish).
28. Liu L, Lu W, Ma Z and Li Z: Oxymatrine attenuates bleomycin-induced pulmonary fibrosis in mice via the inhibition of inducible nitric oxide synthase expression and the TGF-/Smad signaling pathway. Int J Mol Med 29: 815-822, 2012.
29. Song JS, Kang CM, Kang HH, et al: Inhibitory effect of CXC chemokine receptor 4 antagonist AMD3100 on bleomycin induced murine pulmonary fibrosis. Exp Mol Med 42: 465-472, 2010.
30. Chen YL, Zhang X, Bai J, et al: Sorafenib ameliorates bleomycin-induced pulmonary fibrosis: potential roles in the inhibition of epithelial-mesenchymal transition and fibroblast activation. Cell Death Dis 4: e665, 2013.
31. Dong X, Dong J, Zhang R, Fan L, Liu L and Wu G: Anti-inflammatory effects of tanshinone IIA on radiation-induced microglia BV-2 cells inflammatory response. Cancer Biother Radiopharm 24: 681-687, 2009.
32. Fan GW, Gao XM, Wang H, et al: The anti-inflammatory activities of Tanshinone IIA, an active component of TCM, are mediated by estrogen receptor activation and inhibition of iNOS. J Steroid Biochem Mol Biol 113: 275-280, 2009.
33. Fang J, Xu SW, Wang P, et al: Tanshinone II-A attenuates cardiac fibrosis and modulates collagen metabolism in rats with renovascular hypertension. Phytomedicine 18: 58-64, 2010.
34. Kinnula VL, Fattman CL, Tan RJ and Oury TD: Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. Am J Respir Crit Care Med 172: 417-422, 2005.
35. Todd NW, Luzina IG and Atamas SP: Molecular and cellular mechanisms of pulmonary fibrosis. Fibrogenesis Tissue Repair 5: 11, 2012.
36. Chan P, Liu JC, Lin LJ, et al: Tanshinone IIA inhibits angiotensin II-induced cell proliferation in rat cardiac fibroblasts. Am J Chin Med 39: 381-394, 2011.
37. Zhang X, He D, Xu L and Ling S: Protective effect of tanshinone IIA on rat kidneys during hypothermic preservation. Mol Med Rep 5: 405-409, 2012.
38. Chiu TL and Su CC: Tanshinone IIA induces apoptosis in human lung cancer A549 cells through the induction of reactive oxygen species and decreasing the mitochondrial membrane potential. Int J Mol Med 25: 231-236, 2010.
39. Nielsen F, Mikkelsen BB, Nielsen JB, Andersen HR and Grandjean P: Plasma malondialdehyde as biomarker for oxidative stress: reference interval and effects of life-style factors. Clin Chem 43: 1209-1214, 1997.
40. Jeon SJ, Son KH, Kim YS, Choi YH and Kim HP: Inhibition of prostaglandin and nitric oxide production in lipopolysaccharide-treated RAW 264.7 cells by tanshinones from the roots of Salvia miltiorrhiza bunge. Arch Pharm Res 31: 758-763, 2008.
41. Sun D, Shen M, Li J, et al: Cardioprotective effects of tanshinone IIA pretreatment via kinin B2 receptor-Akt-GSK-3beta dependent pathway in experimental diabetic cardiomyopathy. Cardiovasc Diabetol 10: 4, 2011.
42. Dong K, Xu W, Yang J, Qiao H and Wu L: Neuroprotective effects of Tanshinone IIA on permanent focal cerebral ischemia in mice. Phytother Res 23: 608-613, 2009.
43. Hsu YC, Wang LF and Chien YW: Nitric oxide in the pathogenesis of diffuse pulmonary fibrosis. Free Radic Biol Med 42: 599-607, 2007.
44. Genovese T, Cuzzocrea S, Di Paola R, et al: Inhibition or knock out of inducible nitric oxide synthase result in resistance to bleomycin-induced lung injury. Respir Res 6: 58, 2005.
45. Chen TH, Hsu YT, Chen CH, Kao SH and Lee HM: Tanshinone IIA from Salvia miltiorrhiza induces heme oxygenase-1 expression and inhibits lipopolysaccharide-induced nitric oxide expression in RAW 264.7 cells. Mitochondrion 7: 101-105, 2007.
46. Speyer CL, Neff TA, Warner RL, et al: Regulatory effects of iNOS on acute lung inflammatory responses in mice. Am J Pathol 163: 2319-2328, 2003.